Amendments
1997—Subsec. (a). [Pub. L. 105–115, § 125(b)(2)(G)], struck out “, certification of such drug for such disease or condition under [section 357 of this title],” before “or licensing of such drug” in closing provisions.
Subsec. (a)(1) to (3). [Pub. L. 105–115, § 125(b)(2)(F)], inserted “or” at end of par. (1), redesignated par. (3) as (2), and struck out former par. (2), which read as follows: “if the drug is an antibiotic, it may be certified for such disease or condition under [section 357 of this title], or”.
1985—Subsec. (a). [Pub. L. 99–91] struck out “or” at end of par. (1), inserted par. (2), redesignated former par. (2) as (3) and struck out “before” after “product,”, and in last sentence inserted provisions relating to certification of such drug for disease or condition under [section 357 of this title] and substituted “licensing of such drug for such disease or condition under [section 262 of title 42]” for “licensing under [section 262 of title 42] for such disease or condition”.
Effective Date of 1985 Amendment
[Pub. L. 99–91, § 8], Aug. 15, 1985, [99 Stat. 392], provided that:“(a)General Rule.—Except as provided in subsection (b), this Act and the amendments made by this Act [amending this section, sections 360bb, 360cc, and 360ee of this title, and sections 295g–1 and 6022 of Title 42, The Public Health and Welfare, and enacting provisions set out as notes under [section 301 of this title] and [section 236 of Title 42]] shall take effect October 1, 1985.“(b)Exception.—The amendments made by sections 2, 3, and 6(a) [amending this section and sections 360bb and 360cc of this title] shall take effect on the date of the enactment of this Act [Aug. 15, 1985]. The amendment made by section 6(b) [amending [section 6022 of Title 42]] shall take effect October 19, 1984. The amendments made by section 7 [amending [section 295g–1 of Title 42]] shall take effect October 1, 1984 and shall cease to be in effect after September 30, 1985.”
Review Groups on Rare Diseases and Neglected Diseases of the Developing World; Report; Guidance; Standards
[Pub. L. 111–80, title VII, § 740], Oct. 21, 2009, [123 Stat. 2127], provided that:“(a) The Commissioner of Food and Drugs shall establish within the Food and Drug Administration a review group which shall recommend to the Commissioner of Food and Drugs appropriate preclinical, trial design, and regulatory paradigms and optimal solutions for the prevention, diagnosis, and treatment of rare diseases: Provided, That the Commissioner of Food and Drugs shall appoint individuals employed by the Food and Drug Administration to serve on the review group: Provided further, That members of the review group shall have specific expertise relating to the development of articles for use in the prevention, diagnosis, or treatment of rare diseases, including specific expertise in developing or carrying out clinical trials.“(b) The Commissioner of Food and Drugs shall establish within the Food and Drug Administration a review group which shall recommend to the Commissioner of Food and Drugs appropriate preclinical, trial design, and regulatory paradigms and optimal solutions for the prevention, diagnosis, and treatment of neglected diseases of the developing world: Provided, That the Commissioner of Food and Drugs shall appoint individuals employed by the Food and Drug Administration to serve on the review group: Provided further, That members of the review group shall have specific expertise relating to the development of articles for use in the prevention, diagnosis, or treatment of neglected diseases of the developing world, including specific expertise in developing or carrying out clinical trials: Provided further, That for the purposes of this section the term ‘neglected disease of the developing world’ means a tropical disease, as defined in section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act ([21 U.S.C. 360n(a)(3)]).“(c) The Commissioner of Food and Drugs shall—“(1) submit, not later than 1 year after the date of the establishment of review groups under subsections (a) and (b), a report to Congress that describes both the findings and recommendations made by the review groups under subsections (a) and (b);“(2) issue, not later than 180 days after submission of the report to Congress under paragraph (1), guidance based on such recommendations for articles for use in the prevention, diagnosis, and treatment of rare diseases and for such uses in neglected diseases of the developing world; and“(3) develop, not later than 180 days after submission of the report to Congress under paragraph (1), internal review standards based on such recommendations for articles for use in the prevention, diagnosis, and treatment of rare diseases and for such uses in neglected diseases of the developing world.”
Study
[Pub. L. 100–290, § 3(d)], Apr. 18, 1988, [102 Stat. 91], directed Secretary of Health and Human Services to conduct a study to determine whether the application of subchapter B of chapter V of the Federal Food, Drug, and Cosmetic Act, [21 U.S.C. 360aa] et seq. (relating to drugs for rare diseases and conditions), and [26 U.S.C. 28] (relating to tax credit) to medical devices or medical foods for rare diseases or conditions or to both was needed to encourage development of such devices and foods and report results of the study to Congress not later than one year after Apr. 18, 1988.
Congressional Findings
[Pub. L. 97–414, § 1(b)], Jan. 4, 1983, [96 Stat. 2049], provided that: “The Congress finds that—“(1) there are many diseases and conditions, such as Huntington’s disease, myoclonus, ALS (Lou Gehrig’s disease), Tourette syndrome, and muscular dystrophy which affect such small numbers of individuals residing in the United States that the diseases and conditions are considered rare in the United States;“(2) adequate drugs for many of such diseases and conditions have not been developed;“(3) drugs for these diseases and conditions are commonly referred to as ‘orphan drugs’;“(4) because so few individuals are affected by any one rare disease or condition, a pharmaceutical company which develops an orphan drug may reasonably expect the drug to generate relatively small sales in comparison to the cost of developing the drug and consequently to incur a financial loss;“(5) there is reason to believe that some promising orphan drugs will not be developed unless changes are made in the applicable Federal laws to reduce the costs of developing such drugs and to provide financial incentives to develop such drugs; and“(6) it is in the public interest to provide such changes and incentives for the development of orphan drugs.”
